HM Payson & Co’s VanEck Pharmaceutical ETF PPH Stock Holding History

HM Payson & Co’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-268	Closed	-$27.7K	–	1197
2025 Q4	$27.7K	Hold	268	–	–	﹤0.01%	788
2025 Q3	$24.2K	Buy	268 +2	+0.8%	+$175	﹤0.01%	809
2025 Q2	$23.4K	Buy	266 +167	+169%	+$14.5K	﹤0.01%	764
2025 Q1	$9.05K	Hold	99	–	–	﹤0.01%	866
2024 Q4	$8.56K	Hold	99	–	–	﹤0.01%	852
2024 Q3	$9.43K	Sell	99 -150	-60%	-$14.2K	﹤0.01%	842
2024 Q2	$22.8K	Hold	249	–	–	﹤0.01%	734
2024 Q1	$22.6K	Hold	249	–	–	﹤0.01%	724
2023 Q4	$20.3K	Hold	249	–	–	﹤0.01%	735
2023 Q3	$19.9K	Buy	249 +1	+0.4%	+$81	﹤0.01%	730
2023 Q2	$19.5K	Hold	248	–	–	﹤0.01%	733
2023 Q1	$19.3K	Hold	248	–	–	﹤0.01%	719
2022 Q4	$19.3K	Hold	248	–	–	﹤0.01%	677
2022 Q3	$17K	Hold	248	–	–	﹤0.01%	722
2022 Q2	$19K	Hold	248	–	–	﹤0.01%	730
2022 Q1	$20K	Hold	248	–	–	﹤0.01%	753
2021 Q4	$19K	Buy	+248	New	+$18.4K	﹤0.01%	774

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

HM Payson & Co's PPH Position: Q1 2026 in Review

HM Payson & Co sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 268 shares — an estimated $27.7K sold.

HM Payson & Co first reported a position in PPH in Q4 2021 and held it in 17 quarters. The position peaked at $27.7K in Q4 2025. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

HM Payson & Co reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
HM Payson & Co sold 268 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $27.7K.
HM Payson & Co first reported a position in VanEck Pharmaceutical ETF in Q4 2021 and held it in 17 quarters.
HM Payson & Co's VanEck Pharmaceutical ETF position peaked at $27.7K in Q4 2025.
147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on HM Payson & Co's 13F filing for Q1 2026, filed 13 Apr 2026.